| Literature DB >> 17707958 |
Emmanuel T Akporiaye1, Deborah Bradley-Dunlop, Sandra J Gendler, Pinku Mukherjee, Cathy S Madsen, Tobias Hahn, David G Besselsen, Sharon M Dial, Haiyan Cui, Katrina Trevor.
Abstract
A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/(MIN/+) (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-gamma secretion by lymphocytes.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17707958 PMCID： PMC2364598 DOI： 10.1016/j.vaccine.2007.06.063
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641